Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,629 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,170 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer(OC) | recruiting | Phase 1 / Phase 2 | 72 | Tubulis GmbHINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | recruiting | Phase 1 | 200 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04329494 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | recruiting | Phase 1 | 49 | City of Hope Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06885697 | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | recruiting | Phase 1 | 100 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 90 | Cogent Biosciences, Inc.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04847063 | Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | recruiting | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05483491 | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | recruiting | Phase 1 | 30 | Christian HinrichsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | recruiting | Phase 1 | 282 | Xencor, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors(LNCB74-01) | recruiting | Phase 1 | 145 | NextCure, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05636111 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07690189 | Study of NTB-928 in R/R OC | recruiting | Phase 1 | 90 | TeneoSeven, Inc.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03604315 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | recruiting | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | recruiting | Phase 1 | 150 | Normunity AccelCo, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07470853 | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | recruiting | Phase 1 | 265 | Whitehawk Therapeutics, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT05225363 | Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06792552 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 738 | NextCure, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07665515 | Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(OVACT) | recruiting | Phase 1 | 50 | Epitopea LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | recruiting | Phase 1 / Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06040970 | Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer | recruiting | Phase 1 / Phase 2 | 54 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07042802 | A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 180 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07593092 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors | recruiting | Phase 1 | 90 | Xencor, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06543576 | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | recruiting | Phase 1 / Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06840886 | A Study of PHST001 in Advanced Solid Tumors | recruiting | Phase 1 | 272 | Pheast TherapeuticsINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06188520 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors(CYCAD-1) | recruiting | Phase 1 / Phase 2 | 564 | AstraZenecaINDUSTRY | 5 | Aug 6, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07444814 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 226 | Whitehawk Therapeutics, Inc.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT05603910 | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | recruiting | Phase 1 | 18 | Aaron WolfsonOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05759923 | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours | recruiting | Phase 1 | 40 | Molecure S.A.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT07733505 | Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?(NICE-C) | recruiting | Phase 1 | 10 | Odense University HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06191133 | Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | recruiting | Phase 1 | 24 | Lindsay Ferguson, MDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06529809 | Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06856499 | Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer | recruiting | Phase 1 | 50 | University of Colorado, DenverOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03854110 | A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine(MIROC-1) | recruiting | Phase 1 | 80 | Persevere Therapeutics Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 220 | MOMA TherapeuticsINDUSTRY | 3 | Jul 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 1, 2026source: clinicaltrials